Rgenta Therapeutics Presents Preclinical Data Demonstrating Anti-Tumor Activity of Oral Small Molecule MYB Inhibitor, RGT-61159, in Multiple Models of AML at the 66th American Society of Hematology (ASH) Annual Meeting

Data provide support for planned expanded clinical development of best-in-class RGT-61159 in MYB-dependent hematologic cancers, including AML Potent anti-tumor activity observed, providing further evidence for the promising mechanism of RGT-61159 as the company advances the drug candidate…